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Abstract
Background: Functional aspects of mast cell-neuronal interactions remain poorly understood. Mast cell activation
and degranulation can result in the release of powerful pro-inflammatory mediators such as histamine and
cytokines. Cerebral dural mast cells have been proposed to modulate meningeal nociceptor activity and be
involved in migraine pathophysiology. Little is known about the functional role of spinal cord dural mast cells. In
this study, we examine their potential involvement in nociception and synaptic plasticity in superficial spinal dorsal
horn. Changes of lower spinal cord dura mast cells and their contribution to hyperalgesia are examined in animal
models of peripheral neurogenic and non-neurogenic inflammation.
Results: Spinal application of supernatant from activated cultured mast cells induces significant mechanical
hyperalgesia and long-term potentiation (LTP) at spinal synapses of C-fibers. Lumbar, thoracic and thalamic
preparations are then examined for mast cell number and degranulation status after intraplantar capsaicin and
carrageenan. Intradermal capsaicin induces a significant percent increase of lumbar dural mast cells at 3 hours
post-administration. Peripheral carrageenan in female rats significantly increases mast cell density in the lumbar
dura, but not in thoracic dura or thalamus. Intrathecal administration of the mast cell stabilizer sodium
cromoglycate or the spleen tyrosine kinase (Syk) inhibitor BAY-613606 reduce the increased percent degranulation
and degranulated cell density of lumbar dural mast cells after capsaicin and carrageenan respectively, without
affecting hyperalgesia.
Conclusion: The results suggest that lumbar dural mast cells may be sufficient but are not necessary for capsaicin
or carrageenan-induced hyperalgesia.
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Background
Mast cells are primarily known for their role in Immuno-
globulin E (IgE)-dependent hypersensitivity reactions,
although their role in a wide range of physiological func-
tions including neuroimmune interactions has been
increasingly appreciated [1]. Activation of mast cells
usually results in their degranulation, releasing preformed
mediators, most notably histamine and chemokines while
longer lasting activation results in the release of newly
formed mediators such as cytokines, prostaglandins, and
leukotrienes [2]. Mast cells are often found in proximity
to sensory nerve endings and vasculature and their degra-
nulation can modulate the excitability of nociceptive
nerve endings [3]. They can themselves be activated by
neurogenically-generated mediators such as substance P
[4], various antigens, and inflammatory mediators
released in pathophysiological states [5].
Peripheral mast cell activation is generally considered
pro-inflammatory and pro-nociceptive. Inhibition of per-
ipheral mast cells by chronic degranulation using intra-
plantar compound 48/80 blocks rodent capsaicin
hyperalgesia [6]. Direct pharmacological inhibition by
the often used mast cell “stabilizer” cromolyn also inhi-
bits nociceptive behaviours in the second phase of the
formalin test [7]. Cromolyn further inhibits neurogenic
inflammation and edema induced by substance P or by
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[8]. Multiple substances such as cyclooxygenase (COX)
inhibitors [9] or spleen tyrosine kinase (Syk) inhibitors
[10] are also known to inhibit mast cell activation and
degranulation.
While a functional involvement of peripheral mast
cells in inflammatory pain is well established, the role of
central nervous system (CNS) mast cells is not well
understood. Mast cells are not found in the spinal cord
but mostly in the thalamus [11]. Significant sex differ-
ences and asymmetrical distribution which are estrogen-
dependent are noted in thalamic mast cells in naive ani-
mals [12,13], and after nerve injury [14]. Mast cells have
also been particularly investigated in the cerebral dura
mater in relation to migraine pathophysiology and are
thought to promote neurogenic inflammation and acti-
vation of meningeal nociceptors [15,16]. At the spinal
level, dural mast cells are found at a significant density
at the cervical, thoracic, and lumbar regions [17,18],
although their functional roles have not been studied.
Since little to no white matter separates the lumbar dor-
sal horn from the subarachnoid and dura mater, it is
hypothesized that mediators released from dura mast cells
can reach the superficial laminae, a key relay station for
nociception [19], to modulate synaptic transmission and
nociception. While some of the individual mast cell med-
iators also produced by other immune cells are implicated
in nociception and spinal synaptic transmission [20-22],
the combination of mediators some of which serve anti-
inflammatory and homeostatic functions [1], has not been
specifically studied. To examine this, mast cells were cul-
tured and activated in vitro and the mast cell supernatant
was injected intrathecally to assess nociception. In addi-
tion, the supernatant was applied on the lumbar spinal
cord to measure C-fiber evoked field potentials. Since
intraplantar capsaicin induces spinal long-term potentia-
tion (LTP) [23], a form of synaptic plasticity that amplifies
nociception [19,23], we next examined spinal dural mast
cell degranulation after intradermal capsaicin at various
timepoints in awake conscious rats. We then examined
whether intraplantar carrageenan, a model of non-neuro-
genic sterile peripheral inflammation, induces changes in
number and degranulation of spinal dura and thalamic
mast cells in male and female rats. Finally, we tested
whether two intrathecally administered mast cell inhibi-
tors, sodium cromoglycate (cromolyn) and the Syk inhibi-
tor BAY-613606, are antinociceptive against capsaicin or
carrageenan hyperalgesia.
Results
1. Mast cell mediators can induce persistent nociception
and long-term potentiation at spinal C-fiber synapses
As shown in Figure 1A, intrathecal injection of mast cell
supernatant from mast cells that were stimulated with
either TNP (trinitrophenol) for 24 hours (TNP+24 hr)
or 1 hour (TNP+1 hr) induced significant mechanical
hyperalgesia at particular timepoints, as compared to
supernatant stimulated with phosphate buffer saline
(PBS) (TNP-). Two-way repeated measures analysis of
variance (ANOVA) showed a significant effect of group
(F2, 105 = 4.0, P < 0.05), time (F7, 105 = 11.08, P < 0.01)
and interaction (F14, 105 = 2.35, P < 0.01). Post-hoc ana-
lysis revealed a significantly reduced mechanical thresh-
old value at the 1 day timepoint of the 1 hour
stimulated group as compared to control, but not at
other timepoints. The TNP+24 hr group was signifi-
cantly different from the TNP- group at 4 hours, 1 day,
2 days, and 4 days. None of the mast cell supernatants
produced significant thermal hyperalgesia (Figure 1B).
As for cold allodynia (Figure 1C), the Friedman test
revealed a significant difference across the groups
(Friedman statistic = 10.75, P < 0.01). Individual time-
point comparison with the Mann-Whitney test revealed
significant differences between TNP- and TNP+1 hour
at the 1 day (U = 8; P < 0.05) and 2 days (U = 4; P <
0.05) timepoints, as well as a significant difference
between TNP- and TNP+24 hour at the 1 day (U = 7.5;
P < 0.05) and 2 day (U = 5; P < 0.05) timepoints.
As shown in Figures 1E and 1F, supernatant from
mast cells activated with TNP, but not application of
cell culture medium, administered on the lumbar spinal
cord induced spinal LTP in many animals. If an arbi-
trary criterion of a sustained (more than 2 hours)
greater than 50% increase from baseline (over 30 minute
intervals) is used to define LTP, it was assessed that
none out of 6 control animals showed LTP, 4 out of 6
of 1-hour stimulated TNP animals, and all 6 of 24-hour
stimulated TNP animals. Analysis of the averaged traces
of C-fiber evoked field potentials showed no significant
differences of the supernatant from mast cells activated
for 1 hour with TNP as compared to control (Figure
1E). On the other hand, the supernatant from mast cells
activated for 24 hours with TNP induced a highly signif-
icant increase in the area of C-fiber evoked field poten-
tials as compared to control (Figure 1F) (P < 0.05). Area
of A-fiber evoked field potentials was unchanged in all
groups tested, as well as the paired pulse ratio, suggest-
ing a post-synaptic effect (data not shown).
Mast cell supernatant used in behavioral and electro-
physiological experiments was analyzed in order to con-
firm mast cell activation and the presence of newly
formed cytokine mediators, tumor necrosis factor-a
(TNFa), interleukin-4 (IL-4), and interleukin-6 (IL-6)
(Figure 1D). While below detection in non-stimulated
mast cell supernatant and in the 1-hour stimulated sam-
ple, TNFa was detected in the 24-hour stimulated sam-
ple at a concentration of 1819 pg/ml. Likewise, IL-4
levels were below detection in non-stimulated mast cell
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Page 2 of 17Figure 1 Mast cell mediators are sufficient to induce persistent nociception and long-term potentiation. Intrathecally injected supernatant
from cultured mast cells activated for 1 hour induces significant mechanical hyperalgesia at 1 day post injection, while supernatant from mast cells
activated for 24 hours induces significant mechanical hyperalgesia at 4 hours, 1 day, 2 days, and 4 days post-injection (* = P < 0.05) (A). No
significant thermal hyperalgesia is seen (B), although cold allodynia is detected at 4 hours and 1 day post injection of supernatant from mast cells
activated for both 1 hour and 24 hours (* = P < 0.05) (C). TNFa, IL-6, and IL-4 are detected in supernatant from 24 hour activated mast cells, and a
lower level of IL-6 is detected in supernatant from 1 hour activated mast cells (BD: below detection). Experiment is representative from mast cell
supernatant obtained from two independent batches of mast cells that were subsequently used in behavioral and electrophysiology experiments
(D). LTP is elicited in 4 out of 6 animals from lumbar spinal application of supernatant of 1-hour stimulated mast cells (E), and in 6 out of 6 animals
from lumbar spinal application of supernatant of 24-hour stimulated mast cells (F) (Calibration bars: 100 ms, 0.2 mV).
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at 96 pg/ml in the 24-hour stimulated sample. IL-6 was
also not detected in the non-stimulated mast cell super-
natant, but was just above detection at 0.8 ng/ml in the
1-hour stimulated sample, and at a much higher con-
centration of 83 ng/ml in the 24-hour stimulated sam-
ple. We further tested some samples that had been
primed but not stimulated with TNP versus those not
primed and not stimulated with TNP and did not find
any effect of priming on cytokine levels (data not
shown). These results indicated that the 24 hour TNP
mast cell activation was sufficient enough to induce the
synthesis and release of newly formed cytokines.
2. C-fiber stimulation with capsaicin induces significant
degranulation of lumbar dural mast cells
Lumbar and thoracic dura staining with toluidine blue
revealed a significant number of mast cells both granu-
lated and degranulated throughout the dura (Figure 2A).
No definite anatomical pattern could be established,
although there were sometimes particularly prominent
clusters in the dorsal root entry zone. Degranulated
Figure 2 Mast cell degranulation is increased 3 hours after capsaicin. Mast cells are present in the lumbar dura and can be visualized with
toluidine blue staining as mostly granulated with some being degranulated after vehicle treatment (A) or intensively degranulated after
Compound 48/80 (B). C-fiber stimulation with capsaicin induces a significant increase in percent mast cell degranulation at 3 hours post-injection
in the lumbar dura mater as compared to vehicle (C), but not in the thoracic dura mater (D) (* = P < 0.05). I.p. Compound 48/80 administration
induces a significant increased in percent degranulation in both lumbar and thoracic dura mater (* = P < 0.05) (C, D). There are no significant
changes in granulated, degranulated, or total mast cell density in neither the lumbar (E), nor the thoracic dura mater (F) after Compound 48/80
or capsaicin administration.
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staining and ghostly appearance or by the scattering of
individual granules (Figure 2B).
Animals treated with intradermal capsaicin were com-
pared to vehicle at the 10 minute, 3 hour, and 24 hour
timepoints (Figures 2C-F). As a positive control, an
intraperitoneal injection of Compound 48/80 of 2 mg/kg
which induces significant cranial mast cell degranulation
[15] was used. This induced a significant increase in
percent degranulation in the lumbar dura (t12 = 3.27; P
< 0.01) (Figure 2C) and in the thoracic dura (t12 =2 . 4 7 ;
P < 0.05) (Figure 2D). One-way ANOVA for vehicle and
capsaicin groups revealed a significant effect of group in
percent mast cell degranulation in the lumbar dura (F3,
27 = 7.59; P < 0.01). Post-hoc analysis revealed a signifi-
cant increase at 3 hours post-capsaicin as compared to
vehicle (P < 0.01) (Figure 2C). There was no significant
difference in the percentage of mast cell degranulation
in the thoracic region after capsaicin (Figure 2D).
ANOVA and t-tests showed that granulated, degranu-
lated, and total cell density were not significantly differ-
ent between vehicle and capsaicin groups, or between
vehicle and Compound 48/80 administration in either
the lumbar (Figure 2E) or the thoracic (Figure 2F) dura.
3. Inhibiting dural mast cell degranulation does not
reduce capsaicin hyperalgesia
In order to test whether lumbar dural mast cells are
necessary for capsaicin hyperalgesia, two mast cell inhi-
bitors were used spinally to block lumbar dural mast
cell degranulation. Intrathecal cromolyn pretreatment as
compared to vehicle did not significantly reduce
mechanical hyperalgesia induced by 1% capsaicin
(Figure 3A). Repeated measures two-way ANOVA
revealed a significant effect of time (F7, 91 = 11.83, P <
0.001), but no significant effect of group or interaction.
Since 1% capsaicin may be confounded by stress effects
particularly in the initial phase of flinching and primary
hyperalgesia, we also tested a 0.2% capsaicin dose to bet-
ter measure mechanical hyperalgesia and initial flinching
behaviors. We did not detect significant reductions in
flinching behaviors with either cromolyn or BAY-
613606 pretreatment (data not shown). Further, pre-
treatment with cromolyn or BAY-613606 failed to
reduce secondary mechanical hyperalgesia (Figure 3B).
Repeated measures two-way ANOVA showed a signifi-
cant effect of time (F7, 147 = 17.86, P < 0.001), but no
significant effect of group or interaction.
In order to show that the mast cell blockers used in
the behavioral experiments did indeed inhibit mast cells,
different groups of animals were injected using the same
administration protocol from behavioral experiments
with cromolyn, BAY-613606, or vehicle prior to 1% cap-
saicin. One way-analysis revealed significant changes in
percent mast cell degranulation between groups in the
lumbar dura (Figure 3C; F3, 27 = 5.47; P < 0.01). Post-
hoc analysis of the lumbar dura with the Dunnett’st e s t
showed that injection of vehicle did not significantly
alter the percent degranulation, but this was decreased
with cromolyn (P < 0.05) and BAY-613606 (P < 0.05), as
compared to no drug. In the thoracic dura (Figure 3D),
one-way ANOVA revealed no significant differences
between groups. One-way ANOVAs of granulated,
degranulated cell density after capsaicin, capsaicin +
vehicle, capsaicin + cromolyn, and capsaicin + BAY-
613606 revealed a significant effect of group for total
mast cell density (F3, 27 = 3.21; P < 0.05) and degranu-
lated mast cell density (F3, 27 = 3.21; P < 0.05) in the
lumbar region (Figure 3E). Post-hoc analysis with Dun-
nett’s test revealed a significant difference for BAY-
613606 as compared to capsaicin + vehicle for both
total cell density (P < 0.05) and degranulated cell density
(P < 0.05). A significant difference in degranulated mast
cell density was also detected by ANOVA in the thor-
acic region (F3, 27 = 3.21 P < 0.05), although neither
individual comparisons to capsaicin alone nor to capsai-
cin + vehicle were found to be significant (Figure 3F).
4. Longer lasting peripheral inflammation with
intradermal carrageenan induces increased lumbar mast
cell density in female rats but not in male rats
Lumbar and thoracic dural mast cells were quantified
after intraplantar carrageenan in male and female rats.
Unlike capsaicin, in male rats, ANOVA showed no sig-
nificant differences in percen td e g r a n u l a t i o ni ne i t h e r
the lumbar (Figure 4A) or thoracic (Figure 4C) dura
mater. ANOVA also showed no significant effect of
group for total, granulated, or degranulated mast cell
d e n s i t yi nl u m b a r( F i g u r e4 E )o rt h o r a c i cd u r a( F i g u r e
4G). Since there are several reports of sex differences
for mast cells in the literature [3,12,14], we also tested
female rats. Here, again, we did not find any significant
differences between groups for percent degranulation in
neither the lumbar dura mater (Figure 4B) nor the thor-
acic dura mater (Figure 4D). However, when examining
cell densities in the lumbar dura mater (Figure 4F), we
found a highly significant effect of group for total mast
cell density (F4, 40 = 6.96; P < 0.001), granulated mast
cell density (F4, 40 = 3.81; P < 0.05), and degranulated
mast cell density (F4, 40 = 7.61; P < 0.001). Post-hoc ana-
lysis revealed that in comparison to vehicle, there was a
highly significant increase in total lumbar mast cell den-
sity and degranulated mast cell density at 24 hours post-
carrageenan (P < 0.001) and at 72 hours post-carragee-
nan (P < 0.01). We also included a dose of 1% carragee-
nan in this analysis which also showed increased lumbar
degranulated mast cell density at 24 hours post-carra-
geenan (P < 0.05). Granulated cell density was
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carrageenan group (P < 0.01) and in the 24 hour 1%
post-carrageenan group (P < 0.05). In the thoracic dura
mater (Figure 4H), ANOVA revealed a significant effect
of group for thoracic degranulated mast cell density
(F4,40 = 3.32; P < 0.05), but not of granulated or total
mast cell density. Post-hoc analysis revealed a significant
increase in degranulated cell density only at the 72
hours post-carrageenan timepoint as compared to vehi-
cle (P < 0.05).
5. Thalamic mast cells are not significantly altered after
3% carrageenan
Mast cells of the posterior caudal half of the thalamus
were quantified from the same animals that were used
for the dural preparation. Mast cells were easily visible
Figure 3 Intrathecally administered mast cell inhibitors reduce mast cell degranulation but not capsaicin hyperalgesia.I n t r a t h e c a l
cromolyn (200 μg) administered prior to intradermal 1% capsaicin (at timepoints shown by ↑) does not reduce mechanical hyperalgesia (A).
There is also no effect of intrathecal cromolyn or BAY-613606 pretreatment on mechanical hyperalgesia (B) induced by 0.2% capsaicin. However,
both BAY-613606 and cromolyn significantly reduce increased percent mast cell degranulation induced by 1% capsaicin in the lumbar dura
mater (C) (* = P < 0.05 as compared to capsaicin alone), but not in the thoracic dura mater (D). BAY-613606, but not cromolyn, further reduces
degranulated and total cell density in the lumbar dura mater (E) (# = P < 0.05 as compared to capsaicin + vehicle) but not in thoracic dura
mater (F).
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Page 6 of 17Figure 4 Mast cell density is increased in the lumbar dura mater at 24 hours and 72 hours post-carrageenan in female rats.
Intraplantar carrageenan does not induce a significant increase in percent degranulation or any changes in total, granulated, or degranulated
cell densities in male rats in the lumbar (A, E) or in thoracic (B, G) dura mater. There is no significant increase in percent mast cell degranulation
after carrageenan treatment in female rats in the lumbar dura mater (B) or in the thoracic dura mater (D). However, intraplantar carrageenan
induces a significant increase in total, granulated and degranulated mast cell densities in the lumbar dura mater at 24 hours post-injection and
in degranulated and total mast cell densities at 72 hours post-injection (* = P < 0.05, ** = P < 0.001) (F). 1% carrageenan also induces increased
total, granulated and degranulated mast cell densities at 24 hours post-injection in the lumbar dura mater (F). Degranulated cell density is
increased in the thoracic dura mater of female rats at 72 hours post-injection (H).
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(Figures 5A and 5B) and were quantified and assessed
for degranulation status, both on the ipsilateral and on
the contralateral sides of 18-20 non-consecutive thala-
mic slices (every second slice was successfully collected).
ANOVA did not reveal significant differences in percent
degranulation after carrageenan and vehicle treatments
neither in the ipsilateral, nor in the contralateral
thalamic hemisphere in male (Figure 5C) and female
rats (Figure 5D). Likewise, there were no significant dif-
ferences in mast cell density after carrageenan and vehi-
cle treatments in male (Figure 5E), or in female rats
(Figure 5F). This result suggests that increased spinal
dural mast cell density after carrageenan treatment in
female rats is a localized effect. We also investigated the
estrous cycle stage at the time of animal sacrifice and
Figure 5 Thalamic mast cell degranulation or density is not changed after carrageenan in neither male nor female rats.T h e r ea r e
significant numbers of mast cells in the posterior thalamus which are usually close to blood vessels (examples in A and B). Male and female
carrageenan-treated rats do not show differences in percent mast cell degranulation as compared to vehicle, and there are also no significant
ipsilateral/contralateral hemisphere differences in percent mast cell degranulation (C, D). Average mast cell number per section is also not
significantly different between carrageenan treatments and vehicle in male and female rats, and there are also no significant ipsilateral/
contralateral hemisphere differences (E, F).
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groups. Our small sample sizes over the different
estrous groups, as well as the conditions in the current
study did not allow statistically relevant correlational
studies with mast cell degranulation.
6. Inhibiting increased degranulated spinal dural mast cell
density does not reduce carrageenan hyperalgesia
As with capsaicin experiments, the antinociceptive
effects of intrathecal administration of the two mast cell
inhibitors, cromolyn and BAY-613606, were also exam-
ined in female rats. Since the peak mast cell degranula-
tion was found at 24 hours post-carrageenan in the
previous experiment, a double injection protocol was
used for drug administration, prior to and at approxi-
mately 24 hours post carrageenan (after a second “base-
line” testing). As compared to intrathecal vehicle,
administration of intrathecal cromolyn or BAY-613606
did not inhibit carrageenan-induced mechanical hyperal-
gesia, either after the first or the second injection (Fig-
ure 6A). On the ipsilateral hindpaw, repeated measures
two-way ANOVA showed only a significant effect of
time (F10, 210 = 186.8; P < 0.001), but no significant
effect of group or interaction, or any differences on the
contralateral hindpaw. For thermal hyperalgesia (Figure
6B), there was also only a significant effect of time (F10,
210 = 30.70 P < 0.001), but no significant effect of group
or interaction, and no differences on the contralateral
hindpaw. As for cold allodynia (Figure 6C), nonpara-
metric repeated measures ANOVA revealed significant
difference between groups on the ipsilateral side (Fried-
man statistic = 6.05 P > 0.05) only. However, one-tailed
Mann-Whitney t-tests revealed no significant differences
at any timepoints between vehicle treatment and cromo-
lyn or BAY-613606.
In order to show that the administration protocol used
in behavioral experiments indeed inhibited mast cells,
we collected dura mater 3 hours after the second injec-
tion from separate groups of animals treated with the
same dosing protocol used in the above behavioral
experiments. Comparing percent degranulation in the
different groups (Figure 6D), one-way ANOVA revealed
ah i g h l ys i g n i f i c a n te f f e c to fg r o u p( F 3, 27 =8 . 8 3 ;P<
0.001). Although there appears to be a reduction with
both cromolyn and BAY-613606, post-hoc analysis
revealed a significant difference only with BAY-613606
(P < 0.05), and no change with vehicle or cromolyn. In
the thoracic dura (Figure 6E), there were no significant
differences between groups. Total mast cell density or
granulated cell density in the lumbar dura mater was
not significantly different between groups. However,
there were differences in degranulated cell density in the
lumbar dura with a significant reduction by both drug
treatments (Figure 6F). One-way ANOVA revealed a
significant effect of group (F3, 27 = 4.05; P < 0.05) and
subsequent post-hoc analysis revealed a significant
decrease of degranulated mast cell density with both
cromolyn (P < 0.05) and BAY-613606 (P < 0.05), as
compared to no drug. There was no effect of the vehicle
injections. In the thoracic dura (Figure 6G), there were
no significant differences in total, granulated, or degra-
nulated cell densities between carrageenan alone, or
with vehicle, cromolyn, or BAY-613606.
Discussion
Dural mast cells have been mainly investigated in the
cerebral dura mater, where density is high and they are
close to sensory nerve endings [24]. Substantial evidence
suggests that they are involved in migraine pathophy-
siology [16]. Mast cell degranulation with systemically-
administered Compound 48/80 activates meningeal
nociceptors, phospho-ERK expression, and spinal tri-
geminal nucleus cFos activation [15]. Mast cell derived
mediators such as serotonin, prostaglandins, and hista-
mine can activate and sensitize meningeal nociceptors
[22] and COX-1 is expressed in dural mast cells [25]. It
is known that lumbar dural mast cell number varies
during development [17], although dural mast cell func-
tion remains under speculation. The current study is the
first systematic examination of lower spinal dura mast
cells in male and female adult rats using two different
pain paradigms.
The position of the spinal cord grey matter close to
the CSF at the lumbar spinal cord level provided
grounds to hypothesize a potential impact of mast cell-
derived mediators on superficial dorsal horn neurons.
Consistent with this hypothesis, application of superna-
tant from activated cultured mast cells, particularly from
those which were longer activated and secreted newly
formed mediators, induced significant mechanical hyper-
algesia and LTP at spinal synapses of C-fibres. This sug-
gests a potential contribution of preformed mediators,
but a much stronger contribution of newly formed med-
iators. One hour stimulation of mast cells with TNP is
sufficient to induce degranulation, release of histamine
and other preformed mediators [26]. Intrathecal hista-
mine administration is pro-nociceptive in mice [27] and
spinal histamine receptor antagonists show anti-nocicep-
tive efficacy in various animal models [28]. Given the
heterogeneity of mast cells between tissues responsible
for their phenotype [1,29] and even within the dura
[17], we believe that using mouse bone-marrow cultured
mast cells which are less homogeneous than their rat
equivalents [30] is still appropriate here. The concentra-
tion of cytokines in supernatant was within the same
range to that detected by spinal in-vivo microdialysis
studies [31] and that of other electrophysiological and
behavioral studies. Interestingly, spinally-applied TNFa
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Page 9 of 17Figure 6 Effect of intrathecally administered mast cell inhibitors on carrageenan hyperalgesia and mast cell degranulation and
density. Intrathecal administration of either cromolyn or BAY-613606 in female rats before and after carrageenan (at timepoints shown by ↑)
does not inhibit mechanical hyperalgesia (A), thermal hyperalgesia (B), or cold allodynia (C). However, BAY-613606 significantly reduces the
percent mast cell degranulation in lumbar dura mater (D) (** = P < 0.001) but not in the thoracic dura mater (E) of female rats, while both
cromolyn and BAY-613606 inhibit the increased degranulated mast cell density induced by carrageenan in female rats in the lumbar dura mater
(F) (* = P < 0.05) but not in the thoracic dura mater (G).
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cord LTP [32], although intrathecal IL-6 in the nano-
gram range induces mechanical allodynia [33]. Other
mediators such as IL-4 or IL-10 produced by mast cells
are not known to be pro-nociceptive [34] and the
release of mast cell mediators may also be a homeostatic
mechanism [35]. While it is interesting to speculate
which specific mediators may be important in inducing
the effects seen in our study, it is likely that the combi-
nation of preformed and newly formed mediators is
physiologically relevant and more important. Persistent
peripheral nociceptive stimuli for greater than 24 hours,
such as in peripheral hindpaw inflammation, may lead
to different combinations of mast cell mediators and
potentially to a more important activation of dural mast
cells than brief peripheral nociceptive stimuli.
Previous studies have shown that peripheral applica-
tion of 1% capsaicin induces LTP at spinal synapses of
C-fibers [23]. In this study, we found that this dose
induces a significantly increased percentage of mast cell
degranulation at 3 hours post-application. Since no dif-
ference was seen between naïve, vehicle, and 10 minutes
post-capsaicin, this suggests that the 3 hour effect is not
due to injection stress or the initial nociceptive beha-
viors induced by capsaicin. This is interesting given that
mast cells can degranulate rapidly within minutes [36].
Nevertheless, the intense afferent barrage produced by
capsaicin appears to switch granulated mast cells to
become degranulated, but not to increase the mast cell
number. While mast cell staining with toluidine blue
allows for clear visualization of degranulation by staining
the granules, it is possible that results may be influenced
by loss of mast cell staining with complete degranula-
tion [37], although we did not detect significant
decreases in cell numbers after treatments. There was
no effect of mast cell inhibition on capsaicin-induced
flinching and both cromolyn and BAY-613606 were
unable to reduce capsaicin mechanical hyperalgesia, sug-
gesting that this increase is not necessary for mechanical
hyperalgesia. Although we were not able to completely
inhibit mast cells, the effects of BAY-613606 were stron-
ger than cromolyn reaching below basal levels.
Carrageenan injection produces a peripheral inflam-
matory stimulus activating afferents from the entire
hindpaw that persists longer than capsaicin. Surprisingly,
we could find no significant mast cell changes in male
rats. However, when we examined female rats, there was
a highly significant increase in lumbar dural mast cell
density at 24 hours post-carrageenan. This density
increase is different from capsaicin and was also seen
with 1% carrageenan. Since we did not see a percent
increase in mast cell degranulation and no changes to
the thoracic region, this could suggest increased loca-
lized infiltration or attraction of mast cells. Interestingly,
mast cells may also be activated to release mediators
without obvious degranulation or in a selective manner
[38] and there exist mucosal, connective, and mixed
types of mast cells in spinal dura with potentially differ-
ent functional significance [17]. It may be speculated
that mast cells may infiltrate t h ed u r aa n da r r i v ei n t a c t
from the peripheral circulation. While in the current
study, we did not attempt to localize the source of mast
cells or their anatomical position on the dura, we did
not find mast cells inside the spinal cord in the 24 hour
carrageenan treated females (data not shown). For
example, it is known that mast cells may cross blood
vessel walls and their mediators may modulate the
blood brain barrier [39,40]. Studies of CNS mast cells
on blood brain/spinal cord barrier regulation in animal
models of pain are lacking.
Mast cells are known to express estrogen receptors
[41] and can be activated by estrogens which increase
calcium influx and enhance degranulation and mediator
release. These effects can be blocked by estrogen recep-
tor antagonists or calcium chelators [42]. The estrous
cycle influences thalamic mast cell degranulation [43]
and hormones can increase mast cell density in rats
[13]. In our study, we did not find any significant
changes in thalamic mast cells in rats after carrageenan,
although we were unable to conclude about the influ-
ence of the estrous cycle. Nevertheless, the brains and
dura mater were collected from the same animals,
thereby further suggesting that the dural mast cell
changes are not widespread. It should also be noted that
thalamic mast cells are implicated in multiple functions
including sexual reproduction [44], blood brain barrier
regulation [40], and stress [45]. Administration of
aspirin, but not morphine, decreases rat thalamic mast
cell numbers [46]. Nevertheless, we report here an intri-
guing mast cell sex difference in the spinal dura mater.
Various studies have suggested an interaction of hor-
mones and sex with mast cells and potentially pain
behaviors. Prevalence of migraine, mast cell diseases,
and immediate-hypersensitivity type reactions are parti-
cularly prominent in female populations and may relate
to hormonal status [47,48]. Changes in estrogen levels
may be linked to migraine attacks in women, perhaps
due to cerebral mast cell interaction [49]. Future studies
may address specifically the role of the estrous cycle on
dural mast cells.
We successfully inhibited capsaicin and carrageenan-
induced changes in lumbar dural mast cells with two
different drugs, although these did not have significant
anti-nociceptive effects. Higher intrathecal dosing or
volume were not deemed appropriate as they either pro-
duced side effects upon injection in the case of cromo-
lyn, or were unable to further reduce mast cell
degranulation in the case of BAY-613606 (data not
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anti-nociceptive when administered in the formalin test
[7]. Cromolyn, known as a “mast cell stabilizer”,h a s
been used in the treatment of asthma and allergic rhini-
tis [50,51]. It reduces neurogenic inflammation and inhi-
bits mast cell mediator release [52]. Cromolyn has also
been suggested to inhibit chloride transport in mast
cells, epithelial, and nerve cells [53], and also inhibit
substance P binding and adenosine-induced plasma
extravasation [54]. The Syk inhibitor BAY-613606 has
been shown to be highly selective for the Syk family of
tyrosine kinases, which are important signaling mole-
cules involved in mast cell activation and degranulation
[55]. When administered orally in rats, it reduces mast
cell degranulation, histamine release, and inflammation,
more potently than cromolyn [56]. Other Syk inhibitors
reduce inflammation in animal models and have been
suggested for clinical treatment of rheumatoid arthritis
and inflammatory bowel syndrome [57]. Like cromolyn,
Syk inhibitors are not fully specific for mast cells since
Syk is expressed on a variety of cell types including
basophils, leukocytes, platelets, dendritic cells and
macrophages [58]. Nevertheless, we found that both cro-
molyn and BAY-613606 administered intrathecally
inhibited increased percentage of mast cell degranula-
tion and degranulated cell density in a localized fashion.
Other potentially more powerful methods of mast cell
inhibition including the use of transgenic animals such
as mast cell-deficient rats [59], or the assessment of dif-
ferent behavioral endpoints will be interesting for use in
future studies.
Conclusion
Our results demonstrate that mast cell mediators may
be sufficient to amplify spinal nociception, although
lumbar dural mast cells do not appear necessary in cap-
saicin hyperalgesia and carrageenan inflammatory pain.
Our results further demonstrate a sex difference in
spinal dural mast cells after carrageenan inflammation.
Future studies can test the role of dural mast cells in
chronic disease animal models, such as for example
back pain [60].
Methods
1. Animals
Animal experiments were approved by the ethic com-
mittees of the Medical University of Vienna and the
Austrian Ministry for Science and Research (BMWF).
These experiments conform to the standards as set out
by the European Union and the International Associa-
tion for the Study of Pain.
Male and female Sprague-Dawley rats (Medical Uni-
versity of Vienna breeding facility; Himberg, Austria),
weighing between 175 and 250 grams, were used for all
experiments. Animals were kept on a 12/12 hour light/
dark cycle and housed 4-6 per cage. Food and water was
provided ad libitum. Behavioral experiments were per-
formed between the hours of 10 AM and 6 PM. Ani-
mals were habituated to the animal facility for
approximately 1 week and were handled by the experi-
menter at least twice prior to the start of behavioral
experiments.
2. Drugs and drug administration
Capsaicin 1% or 0.2% (dissolved in 80% saline, 10% etha-
nol, and 10% Tween 80 with mild heating) and vehicle
were administered intradermally in briefly restrained
awake animals, using a 30 gauge needle in a 25 μl
volume. Carrageenan 3% or 1% (dissolved and vigor-
ously mixed in 100% saline) was administered intrader-
m a l l yu s i n ga3 0g a u g en e e d l ei nav o l u m eo f1 0 0μl,
while the animal was briefly anesthetized with an inhal-
able anesthesia mixture of oxygen, isoflurane, and
nitrous oxide (N2 O). Compound 48/80 (Sigma-Aldrich,
Vienna, Austria) was dissolved in saline and adminis-
tered intraperitoneally using a 25 gauge needle. Sodium
cromoglycate (Sigma-Aldrich, Vienna, Austria) was dis-
solved in saline and BAY-613606 (Sigma-Aldrich,
Vienna, Austria) was prepared in distilled water in a
1 0 ×s t o c ko f1 0m g / m la n dt h e nd i l u t e dt oaf i n a ld o s e
of 1 mg/ml in saline for injection. They were both admi-
nistered intrathecally by lumbar puncture [61] in a 10 μl
volume using a 27 gauge Hamilton syringe, under brief
isoflurane/N2 O anesthesia. Successful injections were
confirmed by a characteristic tail flick.
3. Mast cell activation and supernatant preparation
Mast cell supernatant was prepared as previously
described by [62]. Five-week cultured bone marrow
derived mast cells (in RPMI 1640 medium supplemen-
ted with 10% heat-inactivated fetal calf serum, 2 mM L-
glutamine, antibiotics, 50 μM b-mercaptoethanol, with
addition of 5 ng/ml mouse-recombinant interleukin-3
(IL-3) from two 8-10 week-old C57BL/6 mice were
used. On day 35 of culture, cells were checked by flow
cytometry for the expression of cell surface markers and
were at least 95% pure as indicated by c-kit and FcεRI
expression. Cells were then seeded at 1 million per ml
and primed with immunoglobulin E (1:500) overnight.
24-well plates were coated overnight with phosphate-sal-
ine buffer or 2, 4, 6 trinitrophenyl-bovine serum albu-
min (TNP-BSA) (300 ng/ml) in PBS. Next day, 24-well
plates were blocked with 3% detoxified BSA in PBS.
Cells were then counted by CasyCounter and seeded at
a concentration of 4 million per ml in cell culture med-
ium. Control condition was seeded in a PBS-coated well,
and activations were performed in TNP-BSA coated
wells for 1 hour and 24 hours. After the activation step,
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the supernatant was snap-frozen and kept at -80°C until
use in behavioral and electrophysiological experiments.
W i t h i nt h es a m et i m ep e r i o da s the other experiments,
the supernatant was analyzed in duplicates for cytokines
by ELISA for the presence of TNFa, IL-6, and IL-4 (all
from BD Bioscience) according to the instructions of
the manufacturer.
4. Tissue preparation for mast cell staining and counting
For capsaicin experiments, dura samples were collected
at 10 minutes, 3 hours, and 24 hours post-capsaicin or
vehicle (n = 7 per group). For carrageenan experiments,
dura samples from male and female animals were col-
lected at 3 hours, 24 hours, and 72 hours post-injection
(n = 7-13 per group). The brain was also collected from
most of the carrageenan-treated animals to count mast
cells in the thalamus (n = 6-9 per group). As a positive
control, in order to observe dural mast cell degranula-
tion, Compound 48/80 or saline vehicle was injected
intraperitoneally using a 25 gauge needle at a dose of 2
mg/kg (n = 7 per group). This protocol has been shown
to significantly degranulate cranial dural mast cells and
activate meningeal nociceptors [15]. To inhibit mast
cells in capsaicin experiments (n = 7 per group), 200 μg
of cromolyn, 10 μg of BAY-613606 or vehicle (saline)
was injected intrathecally in 10 μl immediately prior to
capsaicin and dura samples were collected 3 hours post-
capsaicin. To inhibit mast cells in carrageenan experi-
ments (n = 7 per group), the same doses as above of
cromolyn, BAY-613606, or vehicle were injected
intrathecally in 10 μl twice, once immediately prior to
carrageenan administration and once 24 hours after car-
rageenan administration. The dura sample was then col-
lected 3 hours after the second cromolyn injection (27
hours after carrageenan administration).
4.1 Dura Preparation
Animals were deeply anesthetized with ether and trans-
cardially perfused with 25 ml room temperature saline +
heparin (10 U/ml) followed by 175 ml of 4% paraformal-
dehyde (PFA). The entire spinal cord column and skull
were dissected and post-fixed in 4% PFA overnight. The
vertebral column was then dissected one vertebra at a
time and the roots were carefully cut one at a time, in
order to remove the spinal cord with an intact dura.
The spinal cord was then placed in a petri dish with
PBS. The brain was removed from the skull, washed in
PBS, and placed in 20% sucrose overnight, and 30%
sucrose for 2 additional days, prior to being snap-frozen
in isopentane and stored in -80°C until further proces-
sing. Under a magnifying lamp, the lumbar and thoracic
spinal cord segments were separated and the dura was
carefully excised with fine scissors. It was floated on and
spread with the help of a cotton tip on gelatin covered
slides, which were then allowed to air-dry for at least 2
hours before staining.
4.2 Thalamic preparation
For thalamic sections, frozen brains were cut into 20 μm
coronal sections using a cryostat at -25°C. To avoid
double-counting of mast cells, alternating sections were
collected. The posterior/caudal thalamus was identified
with the help of the Paxinos atlas [63] and was localized
during cutting using the shape of the hippocampus as a
landmark. This area contains significant numbers of
mast cells [43] and it includes the lateral thalamic
nuclei, the ventral posteromedial nucleus of the thala-
mus (VPM), and the ventral posterolateral nucleus of
thalamus (VPL), which are suggested to be involved in
discriminative aspects of pain processing [64]. Between
18 and 20 sections per animal were used for mast cell
staining and counting, and were confirmed to be always
within the area of the caudal half section of the
thalamus.
4.3 Mast cell staining
Slides were stained in 0.2% toluidine blue for the dura
and 0.05% toluidine blue for thalamic sections. A 1%
stock solution in 70% ethanol was dissolved in 0.5%
NaCl solution (pH 2.2-2.3) and the slides were
immersed 30 minutes in the above concentrations. They
were then washed twice in distilled water, dehydrated in
a series of increasing concentrations of ethanol, followed
by placement in butyl acetate ester. Samples were cover-
slipped using Eukitt
® mounting medium and were
allowed to dry overnight.
4.4 Counting of mast cells
Mast cell counting was always performed in a blinded
fashion by an experimenter that was unaware of the
sample identity. Criteria for degranulation were agreed
upon between the experimenters and included: loss of
purple staining, fuzzy appearance, distorted shape, or
multiple granules visible in the vicinity of the cell. Inter-
rater reliability of mast cell degranulation status was
found to be approximately 0.95 in a group of samples.
For dura samples and thalamic sections, the entire sur-
face area of the dura or the left and right thalamus were
scanned manually using a light microscope at 200×
magnification and mast cells were classified as either
granulated or degranulated. Pictures of the dura regions
used were then created at 12.5× magnification and the
area was calculated with the help of the Cell D software
(Olympus).
5. In vivo electrophysiology
Electrophysiological recordings were performed as
described elsewhere [65]. Animals were intubated using
a 16 G cannula and mechanically ventilated (Siemens
Servoventilator 900C). Isoflurane in two thirds N2 O
and one third O2 was used to induce (4 vol%
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sia. Surgical level of anaesthesia was verified by stable
arterial blood pressure and the absence of paw withdra-
wal reflexes after pinching the paw. The right femoral
vein and artery were cannulated to allow intravenous
infusions and to monitor arterial blood pressure. Muscle
relaxation was achieved by 2 μgkg
-1 h
-1 pancuronium
bromide intravenously. The left sciatic nerve was dis-
sected free for bipolar electrical stimulation using a silver
hook electrode and was covered with warm paraffin oil.
Lumbar segments L4 and L5 were exposed by laminect-
omy and the dura mater was incised and retracted. Two
metal clamps were used for fixation of the vertebral col-
umn in a stereotactic frame. An agarose pool was then
formed around the exposed spinal segments. The spinal
segments were covered with artificial cerebrospinal fluid
(CSF) which was carefully removed before application of
drugs (see below). C-fibre-evoked field potentials were
recorded with glass electrodes (2-3 MΩ) in laminae I and
II of the spinal cord dorsal horn in response to stimula-
tion of the ipsilateral sciatic nerve at C-fibre strength.
Electrodes were driven by a microstepping motor (SM-6,
Luigs & Neumann, Germany). Recordings were made
with an extracellular amplifier (EXT-02F, NPI Electronic
Instruments, Germany) using a band width filter of 0.1 -
1000 Hz. Signals were monitored on a digital oscilloscope
(Tektronix TDS 210) and digitized at a sampling rate of 5
kHz by an A/D converter (DigiData 1200 Series Inter-
face). As test stimuli, single pulses (0.5 ms, 25 V, which
are suprathreshold for the activation of C-fibres) were
delivered to the sciatic nerve every 5 minutes using an
electrical stimulator (Iso-Stim 01D, npi electronic, Ger-
many). Stable responses for 1 hour served as control.
Control mast cell culture medium, mast cell supernatant
from 1-hour TNP stimulated cells, or mast cell superna-
tant from 24 hour TNP stimulated cells (n = 6 per group)
were diluted 1:5 in artificial CSF. 150 μl of the above sub-
stances were superfused on the spinal cord by means of a
peristaltic pump. Recordings were performed for at least
4 hours. At the end of the experiment animals were
decapitated in deep anaesthesia and the spinal cord
removed to locate the recording site. Rhodamine B
(0.2%) (Sigma-Aldrich, Vienna, Austria) was added to the
pipette solution which consisted of (in mM) NaCl 135,
KCl 5.4, CaCl2 1.8, Hepes 10 and MgCl2 1 and pressure
was applied to the electrode (300 mbar, 1 min). The
spinal cord was then removed, cryofixed and the rhoda-
mine B spot was localized under a fluorescence micro-
s c o p e .A l lr e c o r d i n g sp e r f o r m e ds h o w e dt h a tt h et i po f
the recording electrode was located in lamina I or II.
6. Behavioral assays
Animals were habituated to the testing rooms for 1
week and handled by the experimenters. One day prior
to the experiments and on the day of testing, they were
habituated to the behavioral apparatus for approximately
30 minutes. Experiments were performed by an experi-
menter unaware of treatment groups. Animals were ran-
domized into groups and experiments were blocked
with an appropriate control group present in every
experiment.
6.1 Capsaicin-induced flinching
Nociceptive behaviors after 0.2% capsaicin injections
were quantified by placing rats in clear Plexiglas boxes.
For a period of 5 minutes post-injection, total flinching,
paw elevation, and licking were measured using a stop-
watch. A flinch was timed as persisting for approxi-
mately one second.
6.2 Thermal hypersensitivity
Thermal thresholds were measured using the plantar
Hargreaves Apparatus (Stoelting Europe, Dublin, Ire-
land). The animals were placed on a heated glass floor
(30°C) and the time latency to hindpaw withdrawal (not
due to movement) was measured with application of the
light source on the region caudal to the foot pads.
Three baseline readings were performed and averaged
for analysis. For carrageenan experiments, the contralat-
eral paw was tested first followed by the ipsilateral paw.
6.3 Mechanical hypersensitivity
Mechanical thresholds were measured using a set of
calibrated Von Frey filaments (Stoelting Europe, Dublin,
Ireland) between 0.25 grams and 15 grams in Plexiglas
boxes with animals standing on a wire mesh. For capsai-
cin experiments, the caudal region behind the ipsilateral
footpad was stimulated three times using a three- sec-
ond stimulation in adjacent areas in this same region.
For all other experiments, the central region between
the footpads was stimulated with one 10 second stimu-
lation. The contralateral paw was tested first followed by
the ipsilateral paw. A positive response was counted
when a clear hindpaw withdrawal occurred (1 out of 3
in capsaicin experiments) not due to movement of the
animal. Ascending hairs were presented in a systematic
manner starting with the 2 gram hair. After the first
response was obtained, four additional hairs were pre-
sented using the up-down method based on [66]. The
50% paw withdrawal threshold was then interpolated
using the formula: 50% g threshold = (10
[xf +kδ])/10,000,
where xf = value (in log units) of the final von Frey hair
used; k = tabular value (see [66] for pattern of positive/
negative responses; and δ = mean difference (in log
units) between stimuli in each pattern used.
6.4 Cold hypersensitivity
Cold allodynia testing was performed using the acetone
test. Using a pipette, 50 μlo fa c e t o n ew e r ea p p l i e dt o
the plantar hindpaw center while the animal was stand-
ing on a wire mesh. The animal was observed for 60
seconds and a nociceptive score based on a modified
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scale: 0-no response, 1-brief flicking less than 3 seconds,
2-flicking and other behaviors such as paw elevation or
licking for more than 3 seconds, 3-prolonged flicking
and other behaviors such as paw elevation and licking
for more than 10 seconds).
7. Behavioral experimental design
7.1 Effect of mast cell supernatant on nociception
Supernatant from non-activated mast cells, supernatant
from mast cells activated for 1 hour or 24 hours or cell
culture medium was injected undiluted intrathecally in
male Sprague-Dawley rats (n = 6 per group). Mechanical
hyperalgesia, thermal hyperalgesia, and cold allodynia
was measured at 30 minutes, 2 hours, 4 hours, 24
hours, 48 hours, 4 days, and 1 week post injection.
7.2 Capsaicin nociception and mast cell inhibition
To assess the effect of mast cell inhibition on capsaicin
mechanical hyperalgesia, male animals (n = 8 per group)
were injected intrathecally with cromolyn immediately
prior to intradermal 1% capsaicin. Mechanical hyperal-
gesia was measured on the ipsilateral hindpaw at 30
m i n u t e s ,1h o u r ,1 . 5h o u r s ,2h o u r s ,3h o u r s ,4h o u r s ,
and 24 hours post-capsaicin. The effect of mast cell
inhibition with intrathecal cromolyn and BAY-613606
pretreatment (n = 8 per group) was assessed on 0.2%
capsaicin-induced flinching behaviors and mechanical
hyperalgesia. Flinching behaviors were assessed for the
first 5 minutes after capsaicin, while mechanical hyperal-
gesia was measured starting at 30 minutes, 1 hour, 1.5
hours, 2 hours, 3 hours, 4 hours, and 24 hours post-
capsaicin.
7.3 Carrageenan nociception and mast cell inhibition
To assess the effect of mast cell inhibition on carragee-
nan mechanical hyperalgesia, thermal hyperalgesia, and
cold allodynia, female animals (n = 8 per group) were
injected intrathecally with 200 μgc r o m o l y no r1 0μg
BAY-613606 in 10 μl immediately prior to carrageenan
administration and 24 hours after carrageenan adminis-
tration. Thermal hyperalgesia, mechanical hyperalgesia,
and cold allodynia were measured on both the ipsilateral
and the contralateral hindpaws starting at baseline
(before carrageenan) 1 hour, 2 hours, 3 hours, 4 hours,
approximately 24 hours (2
nd baseline prior to drug
injection), 25 hours (1 hour post second drug injection),
26 hours (2 hours post-second drug injection), 27 hours
(3 hours post-second drug injection), 48 hours (24
hours post-second drug injection), and 72 hours post-
carrageenan (48 hours post-second drug injection).
8. Statistical analyses
All data are expressed as means ± standard error, except
for those of the acetone test which are median ± inter-
quartile range. For the analyses of C-fibre evoked field
potential areas, mechanical withdrawal thresholds, and
thermal latencies, parametric two-way repeated ANO-
V A sw e r eu s e df o l l o w e db yD u n n e t t ’s Test with vehicle
as a control. Electrophysiology data was normalized to
the baseline and 30 minute intervals were averaged
together. For analysis of cold allodynia, non-parametric
Friedman test was performed followed by individual
timepoint comparisons to vehicle using one-tailed non-
parametric Mann-Whitney U-tests. For mast cell counts,
two-tailed t-tests were used to compare vehicle to Com-
pound 48/80. One-way independent measures ANOVA
followed by Dunnett’s post hoc test was used to analyze
percent degranulation, total mast cell density, granulated
mast cell density, and degranulated mast cell density.
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